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a b s t r a c t
Lasofoxifene (las) and bazedoxifene (bza) are third generation selective estrogen receptor modulators
(SERMs) with minimal estrogenic side effects, approved for treatment of postmenopausal osteoporosis. T
cells are involved in the pathology of postmenopausal osteoporosis and previous studies have established
an important role for 17-estradiol (E2) in T cell development and function. E2 causes a drastic thymic
atrophy, alters the composition of thymic T cell populations, and inhibits T cell dependent inﬂammation.
In contrast, the second generation SERM raloxifene (ral) lacks these properties. Although las and bza are
drugs approved for treatment of postmenopausal bone loss, it is of importance to study their effects on
other biological aspects in order to extend the potential use of these compounds. Therefore, the aim of
this study was to investigate if treatment with las and bza affects T lymphopoiesis and T cell dependent
inﬂammation. C57Bl6 mice were ovariectomized (ovx) and treated with vehicle, E2, ral, las or bza. As
expected, E2 reduced both thymus weight and decreased the proportion of early T cell progenitors while
increasingmorematureTcell populations in the thymus. E2also suppressed theTcell dependentdelayed-
type hypersensitivity (DTH) reaction to oxazolone (OXA). Ral and las, but not bza, decreased thymus
weight, while none of the SERMs had any effects on T cell populations in the thymus or on inﬂammation
in DTH. In conclusion, this study shows that treatment with las or bza does not affect T lymphopoiesis or
T cell dependent inﬂammation.
© 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Estrogen deﬁciency is associated with low bone mass and
both human and experimental studies have shown that treat-
ment with 17-estradiol (E2) protects against bone loss (Khosla
et al., 2012). Selective estrogen receptor modulators (SERMs) are
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positive; SP, single-positive; APCs, antigen-presenting cells; ER, estrogen receptor
alpha; ER, estrogen receptor beta; SCID, severe combined immunodeﬁcient; CIA,
collagen-induced arthritis.
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compounds that act as estrogen receptor agonists or antagonists
depending on the tissue. SERMs, exhibiting agonistic effects on
bone, and antagonistic effects on reproductive organs, are efﬁcient
as treatment of postmenopausal osteoporosis. Raloxifene (ral), a
second generation SERM, was the ﬁrst SERM approved for treat-
ment of postmenopausal osteoporosis. The new third generation
SERMs lasofoxifene (las) and bazedoxifene (bza) have even bet-
ter safety proﬁles and are indicated for treatment and prevention
of postmenopausal osteoporosis (Hadji, 2012). It has been sug-
gested that subclinical inﬂammation, with slightly elevated levels
of pro-inﬂammatory cytokines, plays a role in postmenopausal
osteoporosis (Mundy, 2007). Moreover, T cells are critical in the
pathology of estrogen-deﬁcient osteoporosis (Cenci, 2000).
E2 has diverse effects on the immune system such as inhib-
iting both T and B cell development, and stimulating antibody
production (Nilsson and Carlsten, 1994; Kincade et al., 1994;
Rijhsinghani et al., 1996). It has repeatedly been shown that treat-
ment with E2 improves disease development in experimental
models of arthritis (Jansson and Holmdahl, 1989; Nandakumar
et al., 2003; Engdahl et al., 2014), and we have previously
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shown that the second generation SERM ral inhibits experimen-
tal postmenopausal arthritis (Jochems et al., 2007). Interestingly,
preliminary data from our lab show that also las and bza have ben-
eﬁcial effects on disease development and associated bone loss
in postmenopausal collagen-induced arthritis (Andersson et al.,
submitted). We recently reported that las and bza inhibit B lym-
phopoiesis at a later developmental stage compared to E2, and that
they do not increase the number of antibody-producing cells or the
marginal zone B cell population (Bernardi et al., 2014). However,
no previous studies have explored the effects of las and bza on T
cell development.
T lymphocytes develop in the thymus from lymphoid progen-
itor cells which migrate to the thymus from the bone marrow
(Petrie, 2003). The cells initially lack both CD4 and CD8 and are
termed double-negative (DN) T cells, which in turn can be divided
in developmental order into DN1–DN4 subpopulations. DN4 cells
subsequently acquire CD4 and CD8 simultaneously and become
double-positive (DP) T cells before differentiating into mature,
either CD4+ or CD8+ single-positive (SP) T cells, which leave the
thymus and enter the periphery (Rothenberg et al., 2008). Removal
of endogenously produced estrogen by ovariectomy (ovx) results
in increased weight and cellularity of the thymus (Leposavic et al.,
1996). Phenotypical analysis of thymocytes after ovx has revealed
that the increase in thymus cellularity mostly consists of a shift
toward more DP cells and a decrease in DN and SP cells (Leposavic
et al., 1996). Conversely, in both animals and humans, the thymus
involutes dramatically during pregnancy and after treatment with
E2 (Clarke and Kendall, 1994; Hirahara et al., 1994; Marotti et al.,
1984). Histological studies of mouse thymus have shown that both
pregnancy and treatment with E2 reduce the size of the cortex
while the medulla is preserved, implying an E2-mediated loss of
cortical thymocytes (Kendall and Clarke, 2000; Erlandsson et al.,
2001). In addition, treatment with E2 results in reduced thymic T
cell number and a reduced proportion of DP cells, but increased
levels of SP cells and DN1 cells, while the DN2–DN4 populations
decrease (Zoller and Kersh, 2006; Okasha et al., 2001; Okuyama
et al., 1992). However, treatmentwith the second generation SERM
ral only induces a minor thymic atrophy, and in contrast to E2, ral
does not alter the proportions of DP or SP T cells in the thymus
(Erlandsson et al., 2000).
Besides the well-documented effects on T lymphopoiesis,
estrogen also inhibits cutaneous T cell dependent delayed type
hypersensitivity (DTH) reaction (Erlandsson et al., 2000; Carlsten
et al., 1989). In the skin DTH model, a hapten is applied topically
on abdominal skin whereby sensitization occurs. The immuno-
genic hapten-host protein complex is presented to T cells by
antigen-presenting cells (APCs), ultimaltely resulting in clonal T cell
proliferation. Reappliedhapten induces the elicitationphasewhere
primed T cellsmigrate rapidly to the hapten-exposed skin, produce
cytokines and induce inﬂammation (Honda et al., 2013). We have
previously reported that, in contrast to E2, ral cannot inhibit the
DTH reaction (Erlandsson et al., 2000). The effects of las and bza on
T cell development and function needs further investigation, there-
fore, the aim of this study was to explore the role of las and bza on
T lymphopoiesis and cutaneous T cell dependent inﬂammation.
Materials and methods
Mice
This study was approved by the ethical committee for ani-
mal experiments in Gothenburg. Female C57Bl6N mice (Scanbur,
NOVA-SCB AB, Sollentuna, Sweden) were kept in groups of 4–5
animals per cage under standard environmental conditions and fed
soy-free chow and tap water ad libitum.
Ovariectomy
Micewere ovariectomized (ovx) at the age of 8weeks. Surgeries
were performed under full anesthesia using Isoﬂurane (Bax-
ter Healthcare Corporation Chicago, Illinois, USA). Ovaries were
removed throughamidline skin incision followedbyﬂank incisions
of the peritoneum, and the skinwas closedwithmetallic clips.Mice
received Carprofen (Rimadyl®, Orion Pharma Animal Health, Sol-
lentuna, Sweden) as post-operative analgesia and were allowed to
rest for 10 days after surgery before initiation of treatment.
Hormones and treatment
For the studies of T lymphopoiesis, mice were subcutaneously
injected for 16 consecutive days with 17-estradiol-3-benzoate
(E2; 1g/mouse/day, Sigma–Aldrich, St. Louis, MO, USA), ralox-
ifene (ral; 60g/mouse/day, Sigma–Aldrich), lasofoxifene (las;
4g/mouse/day, Pﬁzer Inc., NY, USA) or bazedoxifene (bza;
24g/mouse/day, Pﬁzer) dissolved in 100l miglyol oil (Vendico
Chemical AB, Malmö, Sweden). Bza and las were kind gifts from
Pﬁzer. Control mice received miglyol oil only (100l/mouse/day).
It has previously been shown that mice treated with E2 in doses
similar to the one used here obtain serum E2 levels corresponding
to low diestrus levels (10–25pg/ml) (Offner et al., 2000). The doses
of ral, las and bza, were chosen based on our previous ﬁnding that
they cause a signiﬁcant increase in total bone mineral density in
ovx mice (Bernardi et al., 2014). In addition, body surface area cal-
culations ensured that doses of ral, las and bza used in mice were
similar to those used in humans (Reagan-Shaw et al., 2008).
DTH reaction
Treatment with E2, ral, las and bza (doses as described above),
was initiated 1 day before sensitization with the hapten oxazolone
(OXA; Sigma–Aldrich) and administered daily until the mice were
terminated 24h after OXA challenge. Mice were sensitized by top-
ical application of 150l of 3% OXA in ethanol:acetone (3:2) on the
abdomen. Six days later, the mice were challenged through cuta-
neous application of 30l of 1% OXA in ethanol, followed by 30l
of 1% OXA in miglyol oil (Vendico Chemical AB, Malmö, Sweden)
on both sides of the right ear. Ear thickness was measured using
a caliper (Kröplin, Hessen, Germany) 24h after challenge and the
difference in thickness between the challenged ear and the unchal-
lenged ear constituted the DTH reaction. The “no DTH” group was
sensitized and challenged with the diluents without OXA, and
treated with vehicle to serve as a control group.
Tissue collection and single cell preparation
At termination, mice were anesthetized with ketamine
(Ketalar®, Pﬁzer) and medetomidine (Domitor®, Orion Pharma),
bled, and killed by cervical dislocation. Thymi were dissected,
weighed and mashed through 70m ﬁlters. Cells were then
washed in PBS, re-suspended in FACS-buffer containing PBS, 10%
FCS and 1% sodium azide and counted using an automated cell
counter (Sysmex Europe GmbH, Nordenstedt, Germany). In the
DTH experiment, the challenged ear was dissected, split into a
dorsal and a ventral part and digested in 2g/ml Collagenase IV
(Sigma–Aldrich) for 1h at 37 ◦C. The tissue was mashed through a
70m ﬁlter, washed in PBS and resuspended in FACS-buffer and
counted using an automated cell counter (Sysmex).
Flow cytometry analysis
Thymocytes (0.5×106) were stained with CD4-v450, CD25-
APC (BD) and with CD8-FITC, CD44-PerCP (BioLegend), and cells
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Fig. 1. E2, ral, and las but not bza reduce thymus weight. Thymus weight expressed
as percentage of total body weight (a) and thymus cellularity (b) after 16 days
of treatment, n=8–10mice/group. Data are expressed as mean+SEM (**p<0.01,
***p<0.001).
from the ear were stained with CD45-PE, CD11b-v450, Ly6C-
APC-Cy7, TCR-FITC, CD19-PE, CD8-v500, CD4-v450 (BD) and
with CD11c-APC, Ly6G-FITC, MHCII-PerCP, CD45-PerCP (BioLe-
gend). Thymocytes were analyzed in a FACSCanto II (BD) and cells
from the ear in a FACSVerse (BD). All data were further processed
using Flow Jo version 10.0.4 (Three Star Inc., Ashland, USA). Dou-
blets were excluded using a singlet gate. Results are presented as
percentage of the different populations per lymphocytes (thymus)
or live cells (ear).
Statistical analysis
Statistical analyses were performed using IBM SPSS software
version 21 (IBM, Armonk, NY, USA). Normality was graphically
assessed. When positive skewing of the normality was found, the
values were logarithmically transformed before analysis. Exper-
iments were terminated on different days; therefore variation
between days was assessed and corrected for when needed using
ANCOVA, otherwise ANOVA was used. All groups were compared
with vehicle usingDunnett’s post hoc testwhen equal variancewas
found, and Dunnett’s T3 post hoc test when Levene’s test revealed
unequal variance. Data are presented as arithmetic mean+SEM
when values were linear and as geometric mean+SEM when val-
ues were logarithmic. P values <0.05 were considered statistically
signiﬁcant.
Results
E2, ral, and las decrease thymus weight
In order to study the effects of E2 and SERMs on thymus, mice
were treated for 16 consecutive days with E2, ral, las, bza or vehi-
cle. We have previously shown that the administrated doses of E2
and SERMs protect against ovx-induced bone loss (Bernardi et al.,
2014). At termination, the thymus was weighed and the number
of thymocytes was determined. In conjunction with earlier stud-
ies (Erlandsson et al., 2000), E2 and ral both decreased the thymus
weight, expressed as percentage of total body weight (Fig. 1a). In
addition, las signiﬁcantly reduced the thymus weight, however bza
lacked this effect (Fig. 1a). Treatment with E2 decreased the thymic
cellularity but none of the SERMs altered the total number of thy-
mocytes (Fig. 1b).
E2, but not SERMs, alters thymic T cell populations
To investigate how SERMs inﬂuence the composition of thymic
T cell populations, thymocytes were characterized by ﬂow cytom-
etry using CD4 and CD8 to obtain the earliest CD4−CD8− double
negative (DN) population, the subsequent CD4+ CD8+ double pos-
itive (DP) population and the most mature CD4+ single positive
(SP) and CD8+ SP populations (Fig. 2a). The DN population was
divided into DN1–DN4 cells using CD25 and CD44, where DN1 cells
were gated as CD25−CD44+, DN2 cells as CD25+CD44+, DN3 cells as
CD25+CD44−, and DN4 cells as CD25−CD44− (Fig. 2a). Percentages
of these populations after treatment with vehicle, E2 or SERMs are
presented in Fig. 2b–h. Treatment with E2 resulted in an increase
in the DN1 population, and a decrease in the DN2 and DN3 popu-
lations, while the DN4 population remained unchanged. None of
the SERMs altered the DN subpopulations (Fig. 2b–e). In addition,
treatmentwithE2 resulted in a tendency towarddecreasedDPpop-
ulation (Fig. 2f), signiﬁcantly increased CD4+ SP cells (Fig. 2g), and
a tendency toward increased CD8+ SP cells (Fig. 2h). However, the
DP and both SP populations were unchanged after treatment with
SERMs (Fig. 2f–h).
E2, but not SERMs, suppresses T cell dependent DTH
Micewere subjected to OXA-induced skin DTH and treatedwith
E2, ral, las, bza or vehicle from one day before sensitization until
termination 24h after challenge. Before termination, the untreated
andhapten-treatedearsweremeasuredand thedifference in thick-
ness was calculated, rendering a DTH reaction in mm×10−2. In
accordance with earlier studies (Erlandsson et al., 2000), treatment
with E2 mediated suppression in the DTH reaction against OXA,
while this effect was not seen with ral. Similarly to ral, treatment
with las or bza did not suppress DTH (Fig. 3).
Effects of E2 and SERMs on leukocyte populations in the ear after
challenge with OXA
In order to study if any of the treatments altered the composi-
tion of immune cells in the ear after induction of DTH, cells from the
ear challenged with OXA were subjected to ﬂow cytometry. Cells
were gated as CD45+ to include leukocytes only and further divided
into CD3+ and CD19+ cells to analyze T and B cells, respectively. The
total leukocytepopulation, aswell asTandBcells,were increased in
the vehicle-treated DTH group compared with the vehicle-treated
control group that was not subjected to DTH (Fig. 4b–d). However,
no changes in the frequencies of total leukocytes, B or T cells in
the challenged ear were seen with either E2 or SERM treatment
(Fig. 4b–d). In addition, innate immune cells were studied by fur-
ther dividing CD45+ cells into neutrophils (CD11b+Ly6G+LY6C−),
macrophages (CD11b+Ly6G−Ly6C+), CD11c+ cells and T cells
(TCR+). Neutrophils, macrophages, CD11c+ cells, and T cells
were signiﬁcantly enriched in the vehicle-treated DTH group com-
paredwith thevehicle-treatedcontrol group thatwasnot subjected
to DTH. The CD11c+ cell population was decreased after treatment
with E2 and ral, but no other differences were found with any of
the treatments (Fig. 5b–e).
Discussion
In the present studywehave investigated the effects of the third
generation SERMs las and bza on T cell development in thymus
and on hapten-induced DTH – a T cell dependent skin inﬂamma-
tion. We demonstrate that las, similarly to the second generation
SERMral,mediates aminor thymic atrophybut that bza completely
lacks effects on thymus weight and cellularity. Furthermore, we
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Fig. 2. E2 but not SERMs alters thymic T cell populations. (a) Gating strategy for DN1-4, DP and SP cells in thymus. Percentage of thymic lymphocytes of DN1 (b), DN2 (c),
DN3 (d), DN4 (e), DP (f), CD4+ SP (g), CD8+ SP (h) in thymus after 16 days of treatment, n=8–10mice/group. Data are expressed as mean+SEM (*p<0.05, **p<0.01).
show that in contrast to E2, neither las nor bza alter thymic T cell
populations, or suppress inﬂammation in DTH.
Thymic T cell development occurs in a stepwise manner and
requires dynamic migration of T cell progenitors within the thy-
mus and signals from stromal cells, such as cortical epithelial
cells (Takahama, 2006). E2 has previously been shown to increase
the DN1 cells and decrease the DN2 cells implying a block in T
cell development at the earliest stage (Rijhsinghani et al., 1996).
Furthermore, E2 decreases the frequency of DP cells while it
increases the frequencies of the most mature CD4+ and CD8+ SP
cells (Rijhsinghani et al., 1996; Erlandsson et al., 2000). In addition,
E2 treatment decreases the thymic cortex area and reduces epithe-
lial cells in the thymic cortex (Erlandsson et al., 2000; Martin et al.,
1994). The second generation SERM ral does not diminish the cor-
tex area and only gives a slight decrease in cortical epithelial cells
(Erlandsson et al., 2000). Furthermore, ral does not alter the thymic
T cell populations (Erlandsson et al., 2000). In line with previous
studies, we conﬁrmed that E2 caused an increase in the DN1 pop-
ulation and a decrease in the following DN2 and DN3 populations,
implying a block in the transition of DN1 to DN2/DN3 developmen-
tal stages. Moreover, the proportion of CD4+ SP cells was increased
by E2, but opposite to previous studies, we did not ﬁnd a signiﬁcant
decrease in the DP population or an increase in the CD8+ SP pop-
ulation. The discrepancy between our results and previous studies
is most likely due to the lower, more physiological, dose of E2 used
in our study.
None of the SERMs used in this study inﬂuenced populations
of developing T cells in the thymus. Thymic T cell development
is promoted by signals from cortical epithelial cells, and previ-
ous studies have shown effects of E2, but not ral, on these cells
(Erlandsson et al., 2000; Martin et al., 1994). Therefore, it is rea-
sonable to speculate that also las and bza have limited effects
on cortical epithelial cells and that the divergent effects of SERM
and E2 on cortical epithelial cells might explain the differences in
the compounds’ abilities to inﬂuence T cell development. How-
ever, this remains to be investigated. Treatment with E2 also
reduces the number of thymus-homing lymphoid progenitors in
the bone marrow leading to decreased inﬂux of early T cell progen-
itors to the thymus (Zoller and Kersh, 2006). Whether the SERMs
affect these cells in the bone marrow or migration of lymphoid
progenitor cells to the thymus is the subject of further investiga-
tion.
Studies using knock-out mice lacking the different estrogen
receptors have established that estrogen receptor alpha (ER) is
indispensable for E2-mediated alterations of thymic T cell popula-
tions but that ER only partlymediates E2-induced thymic atrophy
(Erlandsson et al., 2001). For full thymus involution, both estro-
gen receptor beta (ER) and the transmembrane-bound estrogen
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Fig. 3. E2 but not SERMs suppress DTH. Difference in mm×10−2 in ear thickness
between ear treated with OXA and untreated ear in mice subjected to DTH and
treated with E2 or SERMs, n=8–10mice/group. Data are expressed as mean+SEM
(**p<0.01, ***p<0.001).
receptor GPR30 are required, in addition to ER (Erlandsson et al.,
2001; Staples et al., 1999; Wang et al., 2008). Las and bza bind with
high afﬁnity to both ER and ER (Gennari, 2006; Komm et al.,
2005), but it is unclear whether they bind to GPR30.
The DTH reaction is characterized by a sensitization phase
involving antigen-presentation to naïve T cells, and an elicitation
phase where the primed T cells migrate to the place of hapten
application and induce inﬂammation (Grabbe and Schwarz, 1998;
Kaplanet al., 2012). Themechanism for the suppressive effects of E2
on DTH is not clear, but E2 is not believed to directly affect T cells
in DTH as female severe combined immunodeﬁcient (SCID) mice
reconstituted with thymocytes from E2-treated mice did not show
a decrease in the DTH response (Taube et al., 1998). Instead, the
E2-mediated inhibition of DTH is believed to involve a decrease in
the antigen presentation to T cells and an alteration of the cytokine
pattern (Salem et al., 2000; Ma et al., 2007). Similarly, E2 treat-
ment reduces the ability of splenic DCs to present antigen to T
cells and to produce proinﬂammatory cytokines in other inﬂamma-
tory models (Liu et al., 2002). Possibly, SERMs lack the suppressive
effects on antigen presentation, which could explain the discrep-
ancy between E2 and SERMs in effects on DTH.
Estrogen plays a complex role in autoimmunity and the
prevalence of many autoimmune diseases has a clear female
preponderance. E2 treatment increases the disease progression
in systemic lupus erythematosus (Hughes and Choubey, 2014;
Whitacre, 2001; Carlsten et al., 1990). Conversely, hormone
replacement therapy including E2 ameliorates rheumatoid arthri-
tis and multiple sclerosis (D’Elia et al., 2003; El-Etr et al., 2011)
and treatment with E2 inhibits experimental models of arthritis
and multiple sclerosis (Jansson and Holmdahl, 1989; Nandakumar
et al., 2003; Engdahl et al., 2014). Our group has previously demon-
strated that ral ameliorates arthritis and protects against bone loss
in experimental collagen-induced arthritis (CIA) (Jochems et al.,
2007). Interestingly, preliminary data show that also las and bza
Fig. 4. Treatmentwith E2 or SERMs does not alter the percentage of adaptive immune cells in ear after DTH induction. OVXmicewere treatedwith E2 or SERMs and subjected
to DTH. Cells from inﬂamed ears were analyzed by ﬂow cytometry. (a) Gating strategy for ear skin T and B cells: a small live gate was made and CD45+ cells were further
divided into CD19+ cells (B cells) and CD19− cells. The CD19− population was then used to gate on CD3+ cells (T cells). Percentage of CD45+ cells (b), CD19+ cells (c) and CD3+
cells (d) of live singlet cells, n=7–10mice/group. Data are expressed as mean+SEM (*p<0.05, **p<0.01).
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Fig. 5. E2 and ral reduce CD11c+ cells in ear after DTH induction. OVX mice were treated with E2 or SERMs and subjected to DTH. Cells from inﬂamed ears were analyzed by
ﬂow cytometry. (a) Gating strategy for ear skin innate immune cells: a live cell gate was made and CD45+ cells were further divided into TCR+ cells (T cells), CD11c+ cells
and CD11b+ cells. CD11b+ cells were further divided into Ly6G+Ly6C+ cells (neutrophils) and Ly6G−Ly6C+ cells (macrophages). Percentage of CD45+ cells (b), macrophages and
monocytes (c), neutrophils (d), CD11c+ cells (e) and T cells (f) of live singlet cells, n=7–10mice/group. Data are expressed as mean+SEM (*p<0.05, **p<0.01, ***p<0.001).
have beneﬁcial effects on arthritis and associated bone loss in CIA
(Andersson et al., submitted). T and B cells are both important in
the pathogenesis of CIA. Since las and bza lack effects on T cell
dependent inﬂammation in the DTH model but ameliorates CIA,
anti-arthritic effects might be attributed to SERM-mediated mod-
ulation of B cells or antigen presenting cells instead.
In conclusion, this study characterized the effects of the third
generation SERMs las and bza on T cells and reveals that las
and bza completely lack effects on T lymphopoiesis, and T cell
dependent inﬂammation in a DTH model. Characterization of
immunomodulatory effects of the anti-osteoporotic SERMs is
important in several aspects: subclinical inﬂammation is a com-
ponent in postmenopausal osteoporosis, and SERMs might be
beneﬁcial in treatment of arthritis and associated inﬂammation-
induced bone loss.
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